AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25687927 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent home‐based rehabilitation program (ProMo)
Number of subjects: 81
Study 25687927 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 81
Study 23935011 — intervention group
Group type: EXPERIMENTAL
Intervention: 4F‐PCC
Number of subjects: 202
Study 23935011 — intervention group
Group type: COMPARATOR
Intervention: Plasma
Number of subjects: 202
Study 21091220 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ 150/12.5 mg
Number of subjects: 0
Study 21091220 — intervention group
Group type: COMPARATOR
Intervention: Valsartan/HCTZ 80/12.5 mg
Number of subjects: 0
Study 18220941 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggrenox (antiplatelet agent)
Number of subjects: 0
Study 18220941 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 0
Study 18220941 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY (free radical trapping agent)
Number of subjects: 0
Study 18220941 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin (neuroprotectant)
Number of subjects: 0
Study 18220941 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine (to aid motor recovery)
Number of subjects: 0
Study 18220941 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (anti-depressant and anxiolytic)
Number of subjects: 0
Study 18220941 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (for prevention of deep vein thrombosis post-stroke)
Number of subjects: 0
Study 15121566 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg daily, oral)
Number of subjects: 214
Study 15121566 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate (intravenous)
Number of subjects: 214
Study 11434791 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care office intervention incorporating meal replacements
Number of subjects: 113
Study 11434791 — intervention group
Group type: COMPARATOR
Intervention: Dietitian-led group intervention not using meal replacements
Number of subjects: 113
Study 11434791 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian-led group intervention incorporating meal replacements
Number of subjects: 113
Study 11434791 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups with weight loss of 5% to 10%
Number of subjects: 113
Study 11434791 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups with weight loss of 10% or greater
Number of subjects: 113
Study 9876475 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose steroid (prednisone or dexamethasone) during remission induction
Number of subjects: 56
Study 9876475 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-maintained remission
Number of subjects: 56
Study 9876475 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental magnesium for hypomagnesemia
Number of subjects: 56
Study 9876475 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 56
Study 8205806 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening intervention
Number of subjects: 0
Study 8205806 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 0
Study 3191636 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency pulsing electromagnetic fields (PEMF) stimulation
Number of subjects: 32
Study 3191636 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PEMF stimulation)
Number of subjects: 32
Study 15118845 — intervention group
Group type: EXPERIMENTAL
Intervention: MPI-routine
Number of subjects: 100
Study 15118845 — intervention group
Group type: EXPERIMENTAL
Intervention: MPI-attenuation
Number of subjects: 100
Study 15118845 — intervention group
Group type: EXPERIMENTAL
Intervention: MPI-scatter
Number of subjects: 100
Study 31188198 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound (US) assessment of regional lymph nodes
Number of subjects: 2859
Study 31822885 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (favipiravir and oseltamivir)
Number of subjects: 168
Study 31822885 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir monotherapy
Number of subjects: 168
Study 31112384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone
Number of subjects: 295
Study 31112384 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 295
Study 31112384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 28365220 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoe with 0mm drop (D0)
Number of subjects: 59
Study 28365220 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoe with 6mm drop (D6)
Number of subjects: 59
Study 28365220 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoe with 10mm drop (D10)
Number of subjects: 59
Study 25400284 — intervention group
Group type: EXPERIMENTAL
Intervention: Viagra (original) 100 mg
Number of subjects: 0
Study 25400284 — intervention group
Group type: COMPARATOR
Intervention: Edyfil (generic) 100 mg
Number of subjects: 0
Study 23840361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa consumption (6 g/d) for two weeks
Number of subjects: 214
Study 23840361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa extract treatment in PBMCs
Number of subjects: 214
Study 21149498 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) monotherapy, 20 mg/weekly
Number of subjects: 487
Study 19395984 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg/d for 1 month, followed by a taper of 30 mg/d for 22 weeks)
Number of subjects: 116
Study 19395984 — intervention group
Group type: COMPARATOR
Intervention: Prednisone and placebo (34 patients)
Number of subjects: 116
Study 19395984 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (33 patients)
Number of subjects: 116
Study 16547904 — intervention group
Group type: EXPERIMENTAL
Intervention: Group reminiscence therapy (9 weekly one-hour sessions)
Number of subjects: 24
Study 16547904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 12879635 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 10974600 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 268
Study 10974600 — intervention group
Group type: COMPARATOR
Intervention: SSRIs (fluoxetine, fluvoxamine, paroxetine, sertraline)
Number of subjects: 268
Study 10974600 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 268
Study 10974600 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide and SSRIs
Number of subjects: 268
Study 9486444 — intervention group
Group type: EXPERIMENTAL
Intervention: High labial W‐shaped ('royal') incisions
Number of subjects: 45
Study 9486444 — intervention group
Group type: COMPARATOR
Intervention: High labial curvilinear incisions
Number of subjects: 45
Study 8465870 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 507
Study 8465870 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 507
Study 8465870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study 2875064 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 48
Study 2875064 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 48
Study 2875064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30204761 — intervention group
Group type: EXPERIMENTAL
Intervention: Mujer Segura intervention
Number of subjects: 0
Study 30204761 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27835713 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (n = 120)
Number of subjects: 241
Study 27835713 — intervention group
Group type: COMPARATOR
Intervention: Same-room treatment (n = 121)
Number of subjects: 241
Study 24867469 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic LLLS
Number of subjects: 38
Study 24867469 — intervention group
Group type: COMPARATOR
Intervention: Multi-port laparoscopic LLLS
Number of subjects: 38
Study 23109680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-enriched formula (treatment B)
Number of subjects: 207
Study 23109680 — intervention group
Group type: COMPARATOR
Intervention: Term formula (treatment A)
Number of subjects: 207
Study 20059798 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based rehabilitation
Number of subjects: 94
Study 20059798 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized assertive intervention (OPUS)
Number of subjects: 94
Study 20059798 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment
Number of subjects: 94
Study 18559364 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-2
Number of subjects: 112
Study 18559364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary leak index (PLI)
Number of subjects: 112
Study 18559364 — intervention group
Group type: EXPERIMENTAL
Intervention: Extravascular lung water (EVLW)
Number of subjects: 112
Study 18559364 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung injury score (LIS)
Number of subjects: 112
Study 18559364 — intervention group
Group type: EXPERIMENTAL
Intervention: Von Willebrand factor (VWF)
Number of subjects: 112
Study 18559364 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF
Number of subjects: 112
Study 18559364 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-1
Number of subjects: 112
Study 18559364 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curves for angiopoietin-2 and VWF
Number of subjects: 112
Study 15608435 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 2.0 mg/day, pyridoxine 25 mg/day, and cobalamin 0.5 mg/day (active VITATOPS medication)
Number of subjects: 285
Study 15608435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 12496750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/d)
Number of subjects: 48
Study 12496750 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/d)
Number of subjects: 48
Study 12496750 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (900 mg/d)
Number of subjects: 48
Study 12496750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrates (group)
Number of subjects: 48
Study 9847260 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage protocol involving screening and 2-year monitoring
Number of subjects: 1749
Study 7659428 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSP (Central post-stroke pain)
Number of subjects: 267
Study 7659428 — intervention group
Group type: COMPARATOR
Intervention: Sensibility tests (temperature, touch, pinprick)
Number of subjects: 267
Study 7659428 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological signs and cerebrovascular lesions
Number of subjects: 267
Study 2669998 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (S)
Number of subjects: 907
Study 2669998 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard plus intermediate-dose methotrexate (SAM)
Number of subjects: 907
Study 2669998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-B immunophenotype
Number of subjects: 907
Study 2669998 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pre-B immunophenotype
Number of subjects: 907
Study 2669998 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS remissions
Number of subjects: 907
Study 1093657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 79
Study 1093657 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 79
Study 30431527 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm (left arm) BP manipulated by adjusting position ABOVE (+30°) and BELOW (−30°) heart level
Number of subjects: 20
Study 30431527 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm (left arm)
Number of subjects: 20
Study 30431527 — intervention group
Group type: EXPERIMENTAL
Intervention: PWV (blood flow method)
Number of subjects: 20
Study 30431527 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance coefficient
Number of subjects: 20
Study 30431527 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-stiffness
Number of subjects: 20
Study 30431527 — intervention group
Group type: EXPERIMENTAL
Intervention: Distensibility coefficient
Number of subjects: 20
Study 30431527 — intervention group
Group type: EXPERIMENTAL
Intervention: PWV (Bramwell-Hill method)
Number of subjects: 20
Study 30431527 — intervention group
Group type: EXPERIMENTAL
Intervention: PWV (beta-stiffness index method)
Number of subjects: 20
Study 30431527 — intervention group
Group type: COMPARATOR
Intervention: Control arm (right arm) at heart level
Number of subjects: 20
Study 28650589 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART (CD4 >500 cells/μL)
Number of subjects: 399
Study 28650589 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART (CD4 <350 cells/μL)
Number of subjects: 399
Study 24425805 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-involved care (experimental group)
Number of subjects: 62
Study 24425805 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 62
Study 22921481 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram treatment (10mg/day initially, increased to 10-20mg/day)
Number of subjects: 251
Study 20884261 — intervention group
Group type: EXPERIMENTAL
Intervention: High scores on measures of catastrophizing
Number of subjects: 632
Study 20884261 — intervention group
Group type: EXPERIMENTAL
Intervention: High scores on measures of depression
Number of subjects: 632
Study 20884261 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high scores on measures of depression and catastrophizing
Number of subjects: 632
Study 20884261 — intervention group
Group type: COMPARATOR
Intervention: Low scores on measures of depression and catastrophizing
Number of subjects: 632
Study 19457141 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg/day
Number of subjects: 709
Study 19457141 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 100 mg/day
Number of subjects: 709
Study 19457141 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg/day (responders who discontinued therapy)
Number of subjects: 709
Study 19457141 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 100 mg/day (nonresponders who entered rollover study ETV-901)
Number of subjects: 709
Study 17183973 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of cerebral venous thrombosis during pregnancy and puerperium
Number of subjects: 0
Study 17183973 — intervention group
Group type: COMPARATOR
Intervention: General management rules for venous thrombosis
Number of subjects: 0
Study 14627785 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab 1 mg/kg/week
Number of subjects: 597
Study 14627785 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab 2 mg/kg/week
Number of subjects: 597
Study 14627785 — intervention group
Group type: COMPARATOR
Intervention: Efalizumab (1 or 2 mg/kg/week)
Number of subjects: 597
Study 14627785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 597
Study 14627785 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab (after discontinuation at week 24)
Number of subjects: 597
Study 16786816 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT) for 12 weeks
Number of subjects: 72
Study 10371474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin, 1 g/1,000 mL, amnioinfusion
Number of subjects: 183
Study 10371474 — intervention group
Group type: COMPARATOR
Intervention: Normal saline amnioinfusion
Number of subjects: 183
Study 8688279 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid (polygeline, Haemaccel) 8 ml kg‐1 (n = 15)
Number of subjects: 45
Study 8688279 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaraminol 5 micrograms kg‐1 and 1.7 micrograms kg‐1 min‐1 (n = 15)
Number of subjects: 45
Study 8688279 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of colloid and metaraminol (n = 15)
Number of subjects: 45
Study 1807303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises
Number of subjects: 66
Study 1807303 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 66
Study 6575576 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 tablets (Prostin)
Number of subjects: 193
Study 6575576 — intervention group
Group type: COMPARATOR
Intervention: Demoxytocin resoriblets (Sandopart)
Number of subjects: 193
Study 29038320 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (booster dose at 4 years of age)
Number of subjects: 332
Study 29038320 — intervention group
Group type: COMPARATOR
Intervention: 4CMenB vaccine (2 doses at 12-24 months)
Number of subjects: 332
Study 26802155 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib (150 mg daily)
Number of subjects: 79
Study 26802155 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (75 mg b.i.d.)
Number of subjects: 79
Study 26802155 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of selumetinib (150 mg daily) with erlotinib (100 mg daily)
Number of subjects: 79
Study 25139257 — intervention group
Group type: EXPERIMENTAL
Intervention: Professionally-led telephone support intervention
Number of subjects: 202
Study 25139257 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed written intervention
Number of subjects: 202
Study 25139257 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 202
Study 22472632 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse counseling plus after-school physical activity club
Number of subjects: 69
Study 19389560 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Q waves
Number of subjects: 4530
Study 19389560 — intervention group
Group type: COMPARATOR
Intervention: No baseline Q waves
Number of subjects: 4530
Study 17254834 — intervention group
Group type: EXPERIMENTAL
Intervention: Photometric method using Spectrascan650 Photometer
Number of subjects: 24
Study 17254834 — intervention group
Group type: COMPARATOR
Intervention: Photographic grading scale (CCLRU) from 0 (none) to 100 (extreme)
Number of subjects: 24
Study 16160500 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% ophthalmic solution
Number of subjects: 46
Study 16160500 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin 0.3% ophthalmic solution
Number of subjects: 46
Study 12147018 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-cued condition
Number of subjects: 168
Study 12147018 — intervention group
Group type: COMPARATOR
Intervention: No-cue condition
Number of subjects: 168
Study 12147018 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C-cue condition
Number of subjects: 168
Study 9428851 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus clonidine 1 microgram/kg (BC1 group)
Number of subjects: 58
Study 9428851 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus clonidine 2 micrograms/kg (BC2 group)
Number of subjects: 58
Study 9428851 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (P group)
Number of subjects: 58
Study 9428851 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine, 0.25% (B group)
Number of subjects: 58
Study 9428851 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine plus epinephrine 1:200,000 (BE group)
Number of subjects: 58
Study 9428851 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 58
Study 9428851 — intervention group
Group type: EXPERIMENTAL
Intervention: BC1 and BC2 groups
Number of subjects: 58
Study 10150264 — intervention group
Group type: EXPERIMENTAL
Intervention: Feldene Gel (1 g applied topically three or four times daily for 14 days)
Number of subjects: 191
Study 10150264 — intervention group
Group type: COMPARATOR
Intervention: Usual NSAID treatment (continued for 28 days without change in drug or dose)
Number of subjects: 191
Study 2679836 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 80
Study 2679836 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole
Number of subjects: 80
Study 30565338 — intervention group
Group type: EXPERIMENTAL
Intervention: Attribute level overlap
Number of subjects: 3320
Study 30565338 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of level overlap and color coding
Number of subjects: 3320
Study 28499786 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-cm high pillow (HP)
Number of subjects: 20
Study 28499786 — intervention group
Group type: COMPARATOR
Intervention: 4-cm low pillow (LP)
Number of subjects: 20
Study 28499786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral head rotation
Number of subjects: 20
Study 28499786 — intervention group
Group type: COMPARATOR
Intervention: No lateral head rotation
Number of subjects: 20
Study 25724156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg under fasting conditions (study 1)
Number of subjects: 68
Study 25724156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg under fasting conditions in CLL patients (study 2)
Number of subjects: 68
Study 25724156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg given 30 min before a standard breakfast (study 3)
Number of subjects: 68
Study 25724156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib under uncontrolled food-intake conditions (study 2)
Number of subjects: 68
Study 25724156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib in all settings studied
Number of subjects: 68
Study 24581940 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated-dose conformal radiotherapy (74 Gy in 37 fractions)
Number of subjects: 843
Study 24581940 — intervention group
Group type: COMPARATOR
Intervention: Control-dose conformal radiotherapy (64 Gy in 32 fractions)
Number of subjects: 843
Study 21877138 — intervention group
Group type: EXPERIMENTAL
Intervention: Chained sequential operations
Number of subjects: 0
Study 21877138 — intervention group
Group type: COMPARATOR
Intervention: Independent operations
Number of subjects: 0
Study 21959822 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic (KWAI) 300 mg thrice daily + Metformin 500 mg twice daily
Number of subjects: 60
Study 21959822 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Metformin 500 mg twice daily
Number of subjects: 60